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INTRODUCTION
Nucleosides and nucleotides (NS/NT) are essen-
tial components of cells, involved in DNA and RNA
synthesis, as well as protein metabolism (1). Mam-
malian cells can synthesize these components via
de novo pathways and thus, deficiencies do not oc-
cur under normal conditions (1). In the clinical field,
nucleic acids are known to exert profound influence
on nitrogen balance and the immune system (2-4).
Exogenous applications of NS/NT are incorporated
well into somatic cells such as brain tissue, and cells
that undergo rapid-turnover e.g. those involved in
repair or intestinal tissue (5, 6). The capacity of in-
testinal cells for synthesis of NT de novo is limited
by high cell turnover rates (7), as this process re-
quires significant amounts of energy. However, the
salvage pathway requires less energy and thus, can
supplement de novo generation in situations requir-
ing increased synthesis of DNA and RNA (8).
OG-VI is a well-balanced NS/NT mixture com-
prising 30 mM inosine, cytidine and guanosine
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monophosphate, as well as 22.5 mM uridine and
7.4 mM of thymidine. In the clinical setting, OG-VI
is delivered parenterally (9) and in animal models,
it has been shown to increase protein synthesis and
improve nitrogen balance following a partial hepatec-
tomy (9, 10), as well as enhance hepatic DNA syn-
thesis (11). OG-VI has been shown to support in-
testinal mucosal growth via parenteral nutrition (12,
13) following massive bowel resection (14) and dur-
ing fetal small bowel transplantation (15).
In clinical practice, chemotherapy is a highly ef-
fective treatment for neoplasia. However, the che-
motherapeutic agents can cause serious side effects
in the gastrointestinal tract, since they are cytotoxic
for normal, rapid-turnover tissues. The suffering
caused by these side effects often limits the length
of therapy (16, 17), and there has been no way to
avoid this problem until now.
Glutamine (Gln) is the most abundant amino acid
and it is conditionally essential during critical phases
or following intestinal damage, since it is used by
rapid-turnover cells as an important N-source for NT
synthesis (18). Although several authors have dem-
onstrated the advantages of Gln supplements in ani-
mals, showing that it suppresses the intestinal tox-
icity of treatment with chemotherapeutic agents, its
therapeutic benefits remain unclear (19-23). In an
in vitro study, Yamauchi, et al. reported Gln did not
function as an energy source but as an N-donor for
cellular NT synthesis, replacing exogenous NS/NT
during proliferation or growth (24).
In this study, we used an in vitro model to esti-
mate the benefits of exogenous OG- VI treatment
on intestinal toxicity induced by three chemothera-
peutic agents : 5-fluorouracil (5FU), a thymidine syn-
thetase inhibitor that blocks de novo pyrimidine syn-
thesis ; methotrexate (MTX), a folate antagonist that
blocks dihydrofolate reductase and thymidine syn-
thetase ; and 6-mercaptopurine (6MP), an inhibitor
of de novo purine synthesis that depletes cellular
levels of adenine, guanine and ribonucleotides. Fur-
thermore, we evaluated whether or not the sensi-
tivity of intestinal cells to chemotherapeutic agents
varied under conditions of Gln deficiency and OG-
VI supplementation.
MATERIALS AND METHODS
Reagents and Chemicals
OG-VI comprises 30 mM inosine, cytidine and
guanosine monophosphate, 22.5 mM uridine and
7.4 mM thymidine. The total concentration of NS/
NT in stock OG-VI was 120 mM and the final con-
centration of the OG-VI was 1.2 mM (1 : 100 dilu-
tion) in after the experiments. 5FU, MTX and 6MP
were purchased from Wako Pure Chemical Indus-
tries (Osaka, Japan). Stock 5FU (100 μM) was dis-
solved in PBS. Stock MTX (5 μM) and 6MP (1 mM)
were dissolved in 10 and 2 mM of NaOH, respec-
tively.
Cell Culture
Caco-2 human intestinal epithelial cells were main-
tained in DMEM (Sigma), supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and anti-
biotic (50 μg mL-1 gentamycin). Cells were grown
at 37 in a humidified 5% CO2/95% air atmos-
phere. For viability assays, cells (2104 cells/well)
were seeded into 24-well plates in media with or
without Gln, and containing 0.1% antibiotics, 0.1%
MITO+ serum extender (Becton Dickinson) and 1%
modified Eagle medium (MEM) non-essential amino
acids solution (NEAA). Immediately after plating,
OG-VI (1.2 mM) was added to the appropriate wells
and cells were incubated at 37 for 24 h, after
which chemotherapeutic agents (1 μM 5FU, 50
nM MTX or 10 μM 6MP) or vehicle were added
and the incubation continued for a further 7 days.
Cell numbers were evaluated daily. Final OG-VI
concentration (1.2 mM) was selected according to
the optimal dose in in vitro study (1.20.006 mM)
(24) and the blood concentration (5 mM) in in vivo
study (9). Drug concentrations were selected accord-
ing to recognized treatment levels. PBS and NaOH
were used as vehicle controls.
Cell Viability Assay
Following treatment, Caco-2 cells were harvested
by trypsinization and viability was measured using
the trypan blue dye exclusion test, as described pre-
viously (24).
Cell Cycle Analysis
Caco-2 cells (1105 cells/well) were seeded into
6-well plates in the presence or absence of OG-VI
(1.2 mM), then treated with 5FU (1 μM), MTX (50
nM), 6MP (10 μM) or the vehicle controls (PBS
and NaOH). After 72 h treatment, cells were washed
twice with PBS, harvested by trypsinization, fixed
with ice-cold 70% ethanol, treated with RNase A
(50 μg mL-1) and stained with propidium iodide
(50 μg mL-1). Samples and data were analyzed fur-
ther on a Beckman Coulter Epics XL-MCL. Calcu-
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lation of cell cycle distribution was performed using
the Multi Cycle V. 2.53 software package (Phoenix
Flow Systems, CA).
Statistical analyses
Data were expressed as the meanS.D. Statis-
tical analyses were performed using the Student’s
t-test and P - values 0.05 were considered signifi-
cant.
RESULTS
OG-VI promotes cell survival in 5FU-treated Caco-
2 cells
In the presence and absence of Gln, OG-VI sup-
plements recovered the inhibition of Caco-2 cell
growth caused by 1 μM 5FU treatment (Fig. 1). Fol-
lowing 5FU treatment, the number of cells in the
G0/G1 and S phases decreased and increased, re-
spectively (Fig. 2). OG-VI supplements enabled re-
covery of the cell cycle, with progression of treated
cells resembling that of the vehicle control. The
effects of OG-VI were unaltered by Gln supplements.
OG-VI promotes cell survival in MTX-treated Caco-
2 cells
In the presence and absence of Gln, OG-VI sup-
plements recovered the suppression of Caco-2 cell
growth caused by 5nM MTX treatment (Fig. 3). In
the presence of Gln, some growth of MTX-treated
cells was observed. Following MTX treatment, the
number of cells in the G0/G1 and S phases de-
creased and increased, respectively. OG-VI supple-
ments enabled recovery of the cell cycle, with pro-
gression of treated cells resembling the vehicle con-
trol (Fig. 4). The effects of OG-VI were unaltered
by Gln supplements.
OG-VI promotes cell survival in 6MP-treated Caco-
2 cells
Although we observed a small number of Caco-2
Fig. 2. Effects of OG-VI on the cell cycle distribution of 5FU-treated Caco-2 cells.
Cells were grown in culture medium with or without OG-VI for 24 h after which either 1 μM 5FU or vehicle control was added. Cells
were incubated for a further 3 days, prior to cell cycle analysis. (A) Media containing 4 mM Gln. (B) Gln-free media. All media con-
tained 0.1% of MITO+ serum extender and 1% NEAA solution. Values indicate meansSD from three independent determinations.
Significant differences :, compared to the vehicle control (P 0.05) ;#, compared to 5FU + OG-VI (P 0.05).
Fig. 1. Effects of OG-VI on the cell cytotoxicity of 5FU-treated Caco-2 cells.
Cells were grown in culture media with or without OG-VI for 24 h, after which either 1 μM 5FU or vehicle control was added. (A)
Media containing 4 mM Gln. (B) Gln-free media. All media contained 0.1% MITO+ serum extender and 1% NEAA solution. Values
indicate meansSD from three independent determinations. Significant differences :, compared to the vehicle control (P 
0.05) ;#, compared to 5FU + OG-VI (P < 0.05).
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cell growth following treatment with 10 μM 6MP, the
addition of OG-VI returned growth to similar levels
as observed for the vehicle control. In Gln-deficient
conditions, the growth of OG-VI-supplemented cells
was significantly greater than that of the vehicle
control (P 0.05 ; Fig. 5). We observed no signifi-
cant difference in cell progression following 6MP
treatment, suggesting that this agent does not af-
fect the regulation of cell cycling (Fig. 6).
Fig. 4. Effects of OG-VI on the cell cycle distribution of MTX-treated Caco-2 cells.
Cells were grown in culture medium with or without OG-VI for 24 h, after which either 5 nM MTX or the vehicle control was added.
Cells were incubated for a further 3 days, prior to cell cycle analysis. (A) Media containing 4 mM Gln. (B) Gln-free media. All media
contained 0.1% of MITO+ serum extender and 1% NEAA solution. Values indicate meansSD from three independent determina-
tions. Significant differences :, compared to the vehicle control (P 0.05) ;#, compared to MTX + OG-VI (P 0.05).
Fig. 5. Effects of OG-VI on the cell cytotoxicity of 6MP-treated Caco-2 cells.
Cells were grown in culture medium with or without OG-VI for 24 h, after which either 10 μM 6MP or the vehicle control was
added. (A) Media containing 4 mM Gln. (B) Gln-free media. All media contained 0.1% MITO+ serum extender and 1% NEAA
solution. Values indicate meansSD from three independent determinations. Significant differences :, , compared to the vehicle
control (P 0.05) ;#, compared to 6MP + OG-VI (P 0.05).
Fig. 3. Effects of OG-VI on the cell cytotoxicity of MTX-treated Caco-2 cells.
Cells were grown in culture medium with or without OG-VI for 24 h, after which either 5 nM MTX or vehicle control was added. (A)
Media containing 4 mM Gln. (B) Gln-free media. All media contained 0.1% MITO+ serum extender and 1% NEAA solution. Values
indicate meansSD from three independent determinations. Significant differences :, compared to the vehicle control (P 0.05) ;#,
compared to MTX + OG-VI (P 0.05).
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DISCUSSION
In this study, we used the intestinal epithelial
cell line Caco-2 to examine the effects of supplemen-
tation with an NS/NT mixture (OG-VI) on cytotox-
icity caused by several anti-metabolites used in can-
cer chemotherapy. Since it is likely that de novo
NS/NT synthesis is limited in cells treated with
anti-metabolites, their exogenous addition might en-
hance Caco-2 cell proliferation. Previously, He, et al.
reported that no enhancement of Caco-2 cell prolif-
eration was observed in Gln-rich conditions (2 mM
Gln)(25) although exogenous NTs enhanced pro-
liferation in Gln-deficient conditions. Similarly, Sato
et al. reported that addition of exogenous NTs did
not enhance Caco-2 cell proliferation in the pres-
ence of 4 mM Gln (26). These authors concluded
that in Gln-deficient conditions, reduced de novo
synthesis of NTs caused decreased DNA synthe-
sis. Our results indicate that in both Gln-rich and -
deficient conditions, OG-VI enhances the prolifera-
tion of Caco-2 cells treated with anti-metabolites.
Wang, et al. (27) described the effects of OG-VI
addition on a gastric cancer cell line (KATO III) in-
cubated with 5FU and OG-VI for 3 days. They ob-
served that relative to the non-supplemented con-
dition, viable cell numbers dropped significantly in
the OG-VI-supplemented samples. Although this
result appears to be contradictory to our findings,
it may reflect differences in the NS/NT consump-
tion patterns of each cell line. As such, KATO III
cells were predicted to consume more purine than
pyrimidine NTs (27). Furthermore, the uptake of
guanosine, inosine and uridine is efficient in fetal
rat hepatocytes, whereas the uptake of thymidine
and cytidine is not (28). Modulation of prolifera-
tion by exogenous NTs (AMP, GMP, IMP and
CMP, used individually or as a mixture) has been
examined in two intestinal epithelial cell lines
(IEC-6 and HT29) ; only mixed NTs effected IEC-6
proliferation, whereas either the NTs mixture or
AMP effected HT29 proliferation (29). However,
CMP is considered the most effective nucleotide
for IEC-6 proliferation, presumably because exoge-
nous pyrimidines are used prior to purines during
proliferation of some intestinal cell lines (26). Al-
though we did not compare the effect of individual
OG-VI components, we did observe that the com-
plete mixture enhanced proliferation of all the anti-
metabolite treated Caco-2 cells in this study. This
result indicates that the cells are able to use the ex-
ogenous supplements effectively.
With the exception of 6MP-treated cells, we did
not observe significant effects of Gln on the cell
growth. In Gln-deficient conditions, the prolifera-
tion of 6MP-treated cells was significantly greater
in the presence of OG-VI than the vehicle control
alone. This result suggests that exogenous OG-VI
has a greater influence on cell proliferation than Gln
deficiency, providing effective support for cell pro-
liferation via NT salvage synthesis. Sukemori, et al.
(30) reported that in cultured leukemia cells, a 60%
reduction in Gln level enhanced the cytotoxicity of
5FU but not MTX. However, as 6MP interferes with
purine synthesis and Gln is an N-source for purines
base, it might be expected that Gln-deficient condi-
tions will have a greater effect on 6MP cytotoxicity
than either 5FU or MTX (7).
5FU is generally believed to induce the G1-S
phase arrest due to inhibition of thymidine syn-
thetase (31), and MTX is considered to kill cells in
Fig. 6. Effects of OG-VI on the cell cycle distribution of 6MP-
treated Caco-2 cells.
Cells were grown in culture medium with or without OG-VI for
24 h, after which either 10 μM 6MP or the vehicle control was
added. Cells were incubated for a further 3 days, prior to cell
cycle analysis. (A) Media containing 4 mM Gln. (B) Gln-free
media. All media contained 0.1% MITO+ serum extender and
1% NEAA solution. Values indicate meansSD from three in-
dependent determinations. Significant differences :#, compared
to 6MP + OG-VI (P 0.05).
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the S-phase via irreversible binding to dihydrofolate
reductase (32). Thus, both of these anti-metabolites
block the cell cycle in the S phase. In contrast, 6MP
induces the G2-M phase arrest, inhibiting purine
synthesis via increased methyl-thio-IMP levels (33).
We demonstrated that treatment with either 5FU or
MTX resulted in an increase in the percentage of
cells in the S-phase. Furthermore, we showed that
regulation of the cell cycle returned to normal fol-
lowing addition of OG-VI. However, we did not ob-
serve cell cycle differences between the different 6
MP treatment conditions, although vehicle control
and OG-VI-supplemented cells proliferated, whereas
those treated with 6MP alone did not grow. Thus,
5FU- and MTX- treated cells exhibit a different pat-
tern of cell cycle arrest than 6MP-treated cells. The
presence of exogenous NT or OG-VI leads to an
increased RNA and DNA content of murine or rat
intestines (14, 34-36), leading the speculation that
although de novo NT synthesis has been blocked
by each of anti-metabolite, cell cycle regulation re-
turns to normal as a consequence of DNA and RNA
synthesis. Different studies have shown conflicting
results with respect to the effects of exogenous pu-
rine or pyrimidine NS/NT on proliferation and cell
cycle regulation. However, these differences may
relate to the presence or absence of NT receptors on
the cells used. Extracellular nucleotides exert their
effects via ionotropic P2X receptors or G protein-
coupled P2Y receptors, in which the different re-
ceptors are activated by distinct NTs, purines or
pyrimidines (37). Thus, the variations in proliferation
and cell cycle regulation reported by each study
suggest that there are different receptors involved
in each processes and additional experimentation
will be required to elucidate these mechanisms.
Since we have shown that OG-VI supports prolif-
erative cell growth, it is of importance to determine
whether or not supplementation will accelerate tu-
mor growth. In an in vivo study by Usami, et al. (38),
enhanced tumor growth was not observed when
Yoshida sarcoma was implanted into rats and sup-
plemented with OG-VI. In addition, the authors co-
administrated 5FU with the individual NS/NT com-
ponents and determined that thymidine, uridine
and inosine suppressed tumor growth effectively,
whereas 5’-GMP and cytidine did not. Thus, the
utilization of exogenous nucleotides varies with cell
type and NS/NT mixture component, and it is clear
that the responses of different cell types and organs
to exogenous NS/NT supplementation require fur-
ther investigation.
Taken together, our results indicate that exoge-
nous OG-VI supports the proliferation and cell cy-
cle regulation in cells cultured with several anti-
metabolites used in cancer treatment. Its usage could
rescue rapid-turnover cells, such as those of the in-
testine, from the side effects of cancer treatment
and might enable patients to complete chemother-
apy. Further investigations will need to examine the
effectiveness and consumption patterns of exoge-
nous OG-VI on other types of rapid-turnover cells,
as well as on cancer cells.
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